Andrew Weisenfeld

Bio

Andrew has been an investment banker since 1989. Andrew became a senior member of the MTS team in January 2008, primarily responsible for the development of the life sciences and medical technology practices. Prior to joining, Andrew was a Managing Director in Banc of America Securities' Corporate and Investment Banking Healthcare Group. Andrew co-lead the firm's life sciences practice, providing capital raising and strategic advisory services to both publicly traded and private companies. Prior to joining Banc of America in 2003, Andrew was a Managing Director at JP Morgan, leading its Healthcare M&A business across all sectors of healthcare since 1999. Andrew joined Chase Securities, a predecessor company to JP Morgan, in 1997. Prior to joining Chase, Andrew spent over five years in the M&A Group at Merrill Lynch. Throughout his career, Andrew has worked on a range of advisory transactions including acquisitions, sale transactions and strategic relationships. Selected life sciences transactions include Genzyme's acquisition of Bioenvision, the sale of Nabi's Phoslo product and Biologics business to Fresenius and Biotest, respectively, the sale of Corixa to GlaxoSmithKline, the sale of TKT to Shire, Genzyme's acquisition of Impath, the sale of ALZA to J&J, the sale of BioChem Pharma to Shire, Lundbeck's acquisition of Synaptic, Genta's collaboration with Aventis, and the sale of Gilead's oncology assets to OSI. Andrew was also responsible for many of Bank of America's life sciences financings, including private capital raises for Acadia Pharmaceuticals, Acorda Therapeutics, Allos Therapeutics, Memory Pharmaceuticals, Pharmasset, and Poniard Pharmaceuticals. Andrew holds an MBA from The Wharton School at the University of Pennsylvania and a BS from Cornell University.

Career

---

MTS Health Partners LP Senior Managing Director Email: [email protected]